Insider Transactions in Q1 2023 at Opiant Pharmaceuticals, Inc. (OPNT)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2023
|
Craig A Collard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
55,822
-98.21%
|
$1,116,440
$20.0 P/Share
|
|
Mar 02
2023
|
Gabrielle Alison Silver Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,343
-95.72%
|
$466,860
$20.0 P/Share
|
|
Mar 02
2023
|
Richard J Daly Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,800
-87.18%
|
$156,000
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,916
-88.12%
|
$638,320
$20.0 P/Share
|
|
Mar 02
2023
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,751
-79.14%
|
$415,020
$20.0 P/Share
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9,680
-100.0%
|
$193,600
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
82,006
-83.23%
|
$1,640,120
$20.0 P/Share
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Mar 02
2023
|
Roger Crystal Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,100
-100.0%
|
$102,000
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,720
-100.0%
|
$1,254,400
$20.0 P/Share
|
|
Mar 02
2023
|
Michael Sinclair Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
27,450
-100.0%
|
$549,000
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,548
-81.85%
|
$470,960
$20.0 P/Share
|
|
Mar 02
2023
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
Masuoka K. Lorianne Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,000
-75.0%
|
$80,000
$20.0 P/Share
|
|
Mar 02
2023
|
Ann L. Mac Dougall Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,179
-96.45%
|
$563,580
$20.0 P/Share
|
|
Mar 02
2023
|
Thomas T. Thomas Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,375
-91.92%
|
$247,500
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,990
-81.82%
|
$679,800
$20.0 P/Share
|
|
Mar 02
2023
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Mar 02
2023
|
David D O'Toole Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,248
-88.58%
|
$724,960
$20.0 P/Share
|
|
Mar 02
2023
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Jan 27
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
480
-2.18%
|
$9,600
$20.26 P/Share
|
|
Jan 27
2023
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
444
-1.37%
|
$8,880
$20.26 P/Share
|
|
Jan 27
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
610
-3.15%
|
$12,200
$20.26 P/Share
|
|
Jan 27
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,358
-1.77%
|
$27,160
$20.26 P/Share
|
|
Jan 27
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
541
-1.56%
|
$10,820
$20.26 P/Share
|
|
Jan 09
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,183
-1.52%
|
$23,660
$20.2 P/Share
|
|
Jan 09
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
369
-1.65%
|
$7,380
$20.2 P/Share
|
|
Jan 09
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
469
-2.37%
|
$9,380
$20.2 P/Share
|
|
Jan 09
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
415
-1.18%
|
$8,300
$20.2 P/Share
|
|
Jan 05
2023
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
1,313
-3.89%
|
$26,260
$20.2 P/Share
|
|
Jan 05
2023
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,600
-4.35%
|
$32,000
$20.2 P/Share
|
|
Jan 05
2023
|
Mark Jason Heath Ellison Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,806
-8.35%
|
$36,120
$20.2 P/Share
|
|
Jan 05
2023
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,029
-6.07%
|
$100,580
$20.2 P/Share
|
|
Jan 05
2023
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,421
-5.97%
|
$28,420
$20.2 P/Share
|